Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Helen Blake

Interventional Pain Medicine Chesterfield, MO Medical Doctor

NPI 1245438597 CMS profile 56852

14825 North Outer 40 Rd Ste 360, Ste 360, Chesterfield, MO 63017

Open in the dashboard

General payments

$48,283

239 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Helen Blake of Chesterfield, MO is reported in the CMS Open Payments database as having received $48,283 across 239 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,922 24
2024 General $8,552 35
2023 General $10,413 39
2022 General $4,481 28
2021 General $13,691 35
2020 General $1,053 26
2019 General $7,169 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Helen Blake
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Helen Blake were reported at $2,922. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Helen Blake Interventional Pain Medicine median Middle half National median
2019 $7,169 $684 $216–$2,079 $163
2020 $1,053 $382 $122–$1,109 $114
2021 $13,691 $552 $167–$1,554 $132
2022 $4,481 $605 $187–$1,924 $149
2023 $10,413 $671 $195–$1,915 $160
2024 $8,552 $684 $206–$1,837 $164
2025 $2,922 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $18,837 91 payments
  2. AxoGen $10,837 13 payments
  3. Stratus Medical, LLC $10,143 25 payments
  4. Saluda Medical Americas, Inc. $4,147 20 payments
  5. Medtronic, Inc. $767 12 payments
  6. Nevro Corp. $680 6 payments
  7. SPR Therapeutics, Inc $643 12 payments
  8. Stimwave Technologies Incorporated $402 5 payments
  9. Medtronic USA, Inc. $343 9 payments
  10. Foundation Fusion Solutions, LLC $267 2 payments
  11. Other $1,217 44 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $24,275 20 payments
  2. Food and Beverage $10,485 192 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $5,275 6 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,710 6 payments
  5. Travel and Lodging $3,416 12 payments
  6. Education $121 3 payments
Products named General payments · program years 2019–2025
  1. Nimbus $10,143 25 payments
  2. IonicRF Generator $9,566 6 payments
  3. Avance Nerve Graft $5,138 6 payments
  4. PROCLAIM Neuromodulation $2,666 15 payments
  5. Evoke SCS $2,378 12 payments
  6. AXOGUARD NERVE PROTECTOR $1,978 5 payments
  7. AxoGuard Nerve Connector $1,978 5 payments
  8. Evoke $1,770 8 payments
  9. Proclaim IPG $1,691 8 payments
  10. PROCLAIM Neuromodulation $913 5 payments
  11. Other $7,012 134 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

34

Median for Interventional Pain Management: 1,220

Drug cost

$672

Median for Interventional Pain Management: $39,344

Branded share of claims

32.4%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 11 $403
Gabapentin Generic 12 $198
Duloxetine Hcl Generic 11 $71

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Records

239 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record